Post-dilation in TAVI associated to more stroke and more paravalvular regurgitation

Courtesy of Dr. Carlos Fava.

Moderate/severe paravalvular regurgitation (PVR) after TAVR is present in 10%-14% of all cases, according to different series. The treatment of choice is post-dilation, generally effective in most cases. However, this strategy carries a risk of stroke. The true impact of this conduct is still unclear.

Endocarditis infecciosa post TAVI

 

This review analyzed 6 studies that included 5007 patients; 889 of them underwent post-dilation (17.8%). The remaining 4118 patients did not undergo post-dilation (82.2%).

 

Populations were similar, but the group undergoing post-dilation (PD) included more male patients, presented a higher rate of coronary disease, and more frequent presence of New York Heart Association functional class III/IV. No differences were observed as regards EuroSCORElog or ejection fraction.


Also read: “TAVI Without Predilation Is Feasible and Safe”


At 30 days, there were no differences in mortality (odds ratio [OR]: 1.24; 95% confidence interval [CI]: 0.88-1.74; p = 0.22) and acute myocardial infarction (OR: 0.93; 95% CI: 0.46-1.9; p = 0.85). However, the PD group tended to require definitive pacemaker implantation more frequently (OR: 1.28; 95% CI: 0.99-1.67; p = 0.06) and presented higher rates of moderate/severe PVR.

 

In 81% of all cases, PD reduced PVR by at least one grade. The rate of regurgitation remained high in patients who did not undergo PD.

 

At 1-year follow-up, there were no differences as regards mortality (OR: 0.98; 95% CI: 0.61-1.56; p = 0.92); however, among the PD group the prevalence of stroke was higher (10.2% vs. 2.6%; p = 0.0031) and PVR rates continued to be higher (OR: 3.64; 95% CI: 1.96-6.75; p < 0.001).

 

Conclusion

PD significantly improves the rate of PVR. However, careful patient selection is needed to minimize increased risk of stroke.

 

Editorial Comment

The presence of calcium at valve level is one of the greatest challenges for TAVR, and the association between higher-than-mild PVR and worse outcomes is well-known.

 

The rates of coronary or peripheral disease are associated with patients with more comorbidities and valvular calcification. This must be taken into account when deciding on the characteristics of the valve to be implanted.

 

PD has emerged as the strategy of choice for the reduction of PVR, at the cost of higher stroke rates.

 

Correct valvular assessment through an angioTAC and adequate implantation valve selection is of the utmost importance.

 

Second-generation valves have reduced the presence of PVR. The future will surely bring about much improvement in that sense.

 

Courtesy of Dr. Carlos Fava.

 

Original title: Post-Dilation in Transcatheter Aortic Valve Replacement: A Systematic Review and Meta-Analysis.

Reference: Nelson Wang, et al. Journal of Interventional Cardiology 2017;30:204-211.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

One-Year Results of ENCIRCLE: Percutaneous Mitral Valve Replacement in Patients Ineligible for Surgery or TEER

Symptomatic mitral regurgitation (MR) in patients who are not candidates for surgery or transcatheter edge-to-edge repair (TEER) remains a highly complex clinical scenario associated...

Can Coronary CT Angiography Replace Invasive Coronary Angiography in Pre-TAVI Coronary Assessment?

Coronary artery disease coexists in approximately half of patients undergoing transcatheter aortic valve implantation, making coronary assessment prior to the procedure essential. Invasive coronary...

Valve-in-Valve in Small Surgical Aortic Bioprostheses: Balloon-Expandable or Self-Expanding? Three-Year Results from the LYTEN Trial

Dysfunction of small surgical aortic bioprostheses represents a challenging scenario for transcatheter aortic valve replacement in the valve-in-valve setting, due to the higher incidence...

Can TAVI Be Safely Performed in Patients With Bicuspid Aortic Valve?

Bicuspid aortic valve (BAV) represents an anatomical challenge for transcatheter aortic valve replacement (TAVR) due to the frequent presence of elliptical annuli, fibroc calcific...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

OCT- and IVUS-Guided Coronary Angioplasty in Acute Coronary Syndrome: Long-Term Clinical Outcomes

Percutaneous coronary angioplasty (PCI) in patients with acute coronary syndrome (ACS) has reduced mortality in the acute phase. However, recurrent ACS and target vessel...

One-Year Results of ENCIRCLE: Percutaneous Mitral Valve Replacement in Patients Ineligible for Surgery or TEER

Symptomatic mitral regurgitation (MR) in patients who are not candidates for surgery or transcatheter edge-to-edge repair (TEER) remains a highly complex clinical scenario associated...

Can Coronary CT Angiography Replace Invasive Coronary Angiography in Pre-TAVI Coronary Assessment?

Coronary artery disease coexists in approximately half of patients undergoing transcatheter aortic valve implantation, making coronary assessment prior to the procedure essential. Invasive coronary...